Clinical Trial Update: A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of saridegib (IPI-926) in patients with metastatic or locally advanced chondrosarcoma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chondrosarcoma

Drugs mentioned

• saridegib (IPI-926) (saridegib)

Snippet

Sponsor: Infinity Pharmaceuticals, Inc. | Conditions: Conventional Chondrosarcoma | Phase 2 | Status: COMPLETED